CY1118978T1 - Μεθοδοι και συνθεσεις για την αυξηση της αποτελεσματικοτητας των θεραπευτικων αντισωματων με τη χρηση ενωσεων που διεγειρουν τα κυτταρα νκ - Google Patents

Μεθοδοι και συνθεσεις για την αυξηση της αποτελεσματικοτητας των θεραπευτικων αντισωματων με τη χρηση ενωσεων που διεγειρουν τα κυτταρα νκ

Info

Publication number
CY1118978T1
CY1118978T1 CY20171100422T CY171100422T CY1118978T1 CY 1118978 T1 CY1118978 T1 CY 1118978T1 CY 20171100422 T CY20171100422 T CY 20171100422T CY 171100422 T CY171100422 T CY 171100422T CY 1118978 T1 CY1118978 T1 CY 1118978T1
Authority
CY
Cyprus
Prior art keywords
increasing
therapeutic antibodies
effectiveness
compositions
compounds
Prior art date
Application number
CY20171100422T
Other languages
English (en)
Inventor
Andrea Velardi
François Romagne
Original Assignee
Innate Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma S.A. filed Critical Innate Pharma S.A.
Publication of CY1118978T1 publication Critical patent/CY1118978T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

Η παρούσα εφεύρεση αναφέρεται, γενικά, σε μεθόδους και συνθέσεις για την αύξηση της αποτελεσματικότητας των θεραπευτικών αντισωμάτων. Η αποτελεσματικότητα τους ενισχύεται μέσω της αύξησης του μηχανισμού της ADCC. Ειδικότερα, η εφεύρεση αναφέρεται στη χρήση ενός θεραπευτικού αντισώματος σε συνδυασμό με ενώσεις που παρεμποδίζουν έναν ανασταλτικό υποδοχέα ή διεγείρουν έναν υποδοχέα ενεργοποίησης του ΝΚ κυττάρου, ώστε να ενισχυθεί η αποτελεσματικότητα της αγωγής με θεραπευτικά αντισώματα στους ανθρώπους.
CY20171100422T 2003-07-24 2017-04-07 Μεθοδοι και συνθεσεις για την αυξηση της αποτελεσματικοτητας των θεραπευτικων αντισωματων με τη χρηση ενωσεων που διεγειρουν τα κυτταρα νκ CY1118978T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48948903P 2003-07-24 2003-07-24
PCT/IB2004/002636 WO2005009465A1 (en) 2003-07-24 2004-07-23 Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds

Publications (1)

Publication Number Publication Date
CY1118978T1 true CY1118978T1 (el) 2018-01-10

Family

ID=34102889

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100422T CY1118978T1 (el) 2003-07-24 2017-04-07 Μεθοδοι και συνθεσεις για την αυξηση της αποτελεσματικοτητας των θεραπευτικων αντισωματων με τη χρηση ενωσεων που διεγειρουν τα κυτταρα νκ

Country Status (22)

Country Link
US (3) US7803376B2 (el)
EP (2) EP1648507B1 (el)
JP (3) JP5642328B2 (el)
KR (2) KR20060038461A (el)
CN (3) CN104645327A (el)
AU (1) AU2004258747B2 (el)
BR (1) BRPI0412890B8 (el)
CA (1) CA2532547C (el)
CY (1) CY1118978T1 (el)
DK (1) DK1648507T3 (el)
ES (1) ES2619171T3 (el)
HR (1) HRP20170342T1 (el)
HU (1) HUE033129T2 (el)
IL (1) IL172679A (el)
LT (1) LT1648507T (el)
NO (2) NO337619B1 (el)
PL (1) PL1648507T3 (el)
PT (1) PT1648507T (el)
RU (1) RU2396981C2 (el)
SI (1) SI1648507T1 (el)
WO (1) WO2005009465A1 (el)
ZA (1) ZA200601584B (el)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) * 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
CN103467602B (zh) * 2003-07-02 2018-04-10 依奈特制药公司 用于调节nk细胞活性的组合物和方法
US20090191213A9 (en) * 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
CN104645327A (zh) * 2003-07-24 2015-05-27 依奈特制药公司 使用nk细胞增效化合物提高治疗性抗体功效的方法和组合物
US20060240005A1 (en) * 2003-07-24 2006-10-26 Universita Degli Studi Di Perugia Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US20050249723A1 (en) * 2003-12-22 2005-11-10 Xencor, Inc. Fc polypeptides with novel Fc ligand binding sites
AU2005227326B2 (en) * 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
EP1791868B1 (en) 2004-07-01 2011-02-23 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
ES2534288T3 (es) 2004-08-03 2015-04-21 Innate Pharma Composiciones terapéuticas contra el cáncer que seleccionan como objetivo 4Ig-B7-H3
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
DK1831258T4 (en) 2004-12-28 2023-08-28 Innate Pharma Sa Monoklonale antistoffer mod NKG2A
DK1835937T3 (da) 2005-01-06 2012-07-23 Novo Nordisk As Sammensætninger og fremgangsmåder til behandling af virusinfektion
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
JP5295568B2 (ja) 2005-01-06 2013-09-18 ノヴォ ノルディスク アー／エス Ｋｉｒ結合剤およびその使用方法
EP1858925A2 (en) * 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
US20060286092A1 (en) * 2005-05-12 2006-12-21 Zeren Gao Methods of using pNKp30, a member of the B7 family, to modulate the immune system
CA2624189A1 (en) * 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
US7973136B2 (en) * 2005-10-06 2011-07-05 Xencor, Inc. Optimized anti-CD30 antibodies
EP1934260B1 (en) * 2005-10-14 2017-05-17 Innate Pharma Compositions and methods for treating proliferative disorders
BRPI0712953B8 (pt) * 2006-06-30 2021-05-25 Novo Nordisk As anticorpos anti-nkg2a, seu uso, e composição farmacêutica
EP2059536B1 (en) * 2006-08-14 2014-01-08 Xencor, Inc. Optimized antibodies that target cd19
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
DK2222706T4 (en) 2007-12-14 2016-11-21 Novo Nordisk As Antibodies that bind to NKG2D and its use
EP4098661A1 (en) 2007-12-26 2022-12-07 Xencor, Inc. Fc variants with altered binding to fcrn
JP5774312B2 (ja) 2008-01-24 2015-09-09 ノボ・ノルデイスク・エー／エス ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体
US8709411B2 (en) 2008-12-05 2014-04-29 Novo Nordisk A/S Combination therapy to enhance NK cell mediated cytotoxicity
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
JP5719384B2 (ja) * 2010-02-11 2015-05-20 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ３ｄａｄｃｃｎｋｆａｃｓアッセイ
US20130236449A1 (en) 2010-04-21 2013-09-12 Ventirx Pharmaceuticals, Inc. Methods of enhancing antibody-dependent cellular cytotoxicity
AR083957A1 (es) * 2010-11-22 2013-04-10 Innate Pharma Sa Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
MX347514B (es) * 2011-05-25 2017-04-28 Innate Pharma Sa Anticuerpos anti-receptores tipo inmunoglobulina citoliticos (kir) para el tratamiento de trastornos inflamatorios.
AU2012268939B2 (en) 2011-06-17 2017-05-04 Novo Nordisk A/S Selective elimination of erosive cells
WO2012175613A1 (en) 2011-06-21 2012-12-27 Innate Pharma NKp46-MEDIATED NK CELL TUNING
SG10201702421TA (en) 2012-10-02 2017-05-30 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
CA2894908C (en) * 2012-12-20 2022-07-12 Medimmune, Llc Methods of producing immunoconjugates
JP6360077B2 (ja) * 2013-02-20 2018-07-18 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 末梢ｔ細胞リンパ腫の処置における使用のためのｋｉｒ３ｄｌ２に特異的に結合する化合物
US10494433B2 (en) 2013-11-06 2019-12-03 Bristol-Myers Squibb Company Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma
ES2747799T3 (es) * 2014-03-14 2020-03-11 Innate Pharma Anticuerpos para KIR3DL2 humanizados
JP7093612B2 (ja) * 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
EP3161002A1 (en) * 2014-06-27 2017-05-03 Innate Pharma MULTISPECIFIC NKp46 BINDING PROTEINS
DK3193931T3 (da) * 2014-09-16 2020-10-19 Innate Pharma Neutralisering af hæmmende veje i lymfocytter
US10550187B2 (en) 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
EP3209769B1 (en) 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
RS60753B1 (sr) 2015-04-17 2020-10-30 Bristol Myers Squibb Co Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
NZ738068A (en) 2015-05-06 2019-07-26 Snipr Tech Ltd Altering microbial populations & modifying microbiota
JP2018524404A (ja) * 2015-07-07 2018-08-30 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） Ｎｋ細胞殺傷活性を増強する方法および医薬組成物
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
AU2016299166B2 (en) * 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
EP3336184A4 (en) * 2015-08-11 2019-01-23 Osaka University ANTIBODY
EP3359168A4 (en) 2015-10-06 2019-08-07 Regents of the University of Minnesota THERAPEUTIC COMPOUNDS AND METHODS
EP3371221A2 (en) 2015-11-07 2018-09-12 MultiVir Inc. Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
ES2905823T3 (es) 2016-05-20 2022-04-12 Biohaven Therapeutics Ltd Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
CA3026588A1 (en) * 2016-07-01 2018-01-04 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory immune receptor inhibition methods and compositions
CN106635998B (zh) * 2016-09-14 2018-01-09 深圳市默赛尔生物医学科技发展有限公司 抗体调控的双抗原特异性t细胞及其制备方法和应用
KR102530297B1 (ko) 2016-09-27 2023-05-10 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 미생물유전체를 조정함으로써 면역 체크포인트 차단 요법을 증강시키는 방법
CN116672456A (zh) 2016-10-12 2023-09-01 得克萨斯州大学系统董事会 用于tusc2免疫治疗的方法和组合物
WO2018111902A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
AU2018219887A1 (en) 2017-02-08 2019-08-22 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
CA3235295A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
EP3601355A1 (en) 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
CN113896792A (zh) 2017-05-12 2022-01-07 哈普恩治疗公司 间皮素结合蛋白质
JP6647240B2 (ja) * 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
EP3444276A1 (en) 2017-08-17 2019-02-20 Onkocellular Limited Improved cancer treatment using nk cells
MX2020003856A (es) 2017-10-13 2020-08-13 Harpoon Therapeutics Inc Proteinas de union a antigenos de maduracion de celulas b.
JP2020536894A (ja) 2017-10-15 2020-12-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍処置法
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
KR20200135986A (ko) 2018-03-19 2020-12-04 멀티비르 인코포레이티드 종양 억제인자 유전자 치료 및 cd122/cd132 작용제를 포함하는 암 치료를 위한 방법 및 조성물
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
EP4066851A1 (en) 2018-03-25 2022-10-05 SNIPR Biome ApS. Treating & preventing microbial infections
JP2021519771A (ja) 2018-03-30 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍を処置する方法
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
JP2022509942A (ja) 2018-11-16 2022-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗ｎｋｇ２ａ抗体およびその使用
EP3898974A1 (en) 2018-12-21 2021-10-27 Onxeo New conjugated nucleic acid molecules and their uses
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
CN114174537A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 细胞定位特征和组合疗法
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
AU2021416156A1 (en) 2020-12-28 2023-06-22 Bristol-Myers Squibb Company Methods of treating tumors
US20220233693A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Antibody Compositions and Methods of Use Thereof
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
AU2022312698A1 (en) 2021-07-13 2024-01-25 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023081813A1 (en) 2021-11-05 2023-05-11 St. Jude Children's Research Hospital, Inc. Zip cytokine receptors
WO2023111203A1 (en) 2021-12-16 2023-06-22 Onxeo New conjugated nucleic acid molecules and their uses
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2023240182A1 (en) 2022-06-08 2023-12-14 St. Jude Children's Research Hospital, Inc. Disruption of kdm4a in t cells to enhance immunotherapy
WO2024059787A1 (en) 2022-09-16 2024-03-21 St. Jude Children's Research Hospital, Inc. Disruption of asxl1 in t cells to enhance immunotherapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR401702A (fr) 1908-08-04 1909-09-13 Charles Marenghi Et Cie Soc Dispositif permettant d'imiter mécaniquement la mandoline
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
CH686365A5 (de) 1992-10-06 1996-03-15 Werner Hofliger Mobilkran.
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
CN1326565C (zh) * 1997-10-14 2007-07-18 中外制药株式会社 淋巴细胞肿瘤抗体的增强剂
US5843597A (en) 1997-12-01 1998-12-01 Eveready Battery Company, Inc. Ribbed gasket for miniature galvanic cell
JPH11279009A (ja) 1998-03-26 1999-10-12 Sumitomo Chem Co Ltd 除草剤組成物
JP2002510481A (ja) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド 抗体変異体及びその断片
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CN100531798C (zh) 1998-08-11 2009-08-26 拜奥根Idec公司 包括施用抗-cd20抗体的b-细胞淋巴瘤联合疗法
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
AU783899B2 (en) 1999-11-15 2005-12-22 Innate Pharma S.A.S. Novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
PE20010833A1 (es) 1999-12-20 2001-09-08 Siemens Energy And Automation Inc Sistema, procedimiento y aparato para conectar fuentes electricas en serie bajo plena carga
FR2804027B1 (fr) 2000-01-20 2002-08-30 Monoclonal Antibodies Therapeu Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
EP1266014A2 (en) 2000-03-24 2002-12-18 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
AU2002228745A1 (en) * 2000-10-23 2002-05-06 Rajagopalan, Sumati Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma
ATE556092T1 (de) 2000-12-18 2012-05-15 Inst Nat Sante Rech Med Mittel zur diagnose und therapie von ctcl
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
US7858300B2 (en) * 2001-10-19 2010-12-28 Centre Hospitalier Regional Et Universitaire De Tours Methods and compositions to evaluate antibody treatment response
ATE536188T1 (de) 2002-08-14 2011-12-15 Macrogenics Inc Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
JP2006514024A (ja) * 2002-12-23 2006-04-27 イネイト・ファーマ Ｎｋ細胞の増殖に対する効果を有する医薬組成物及びそれを使用する方法
CN103467602B (zh) 2003-07-02 2018-04-10 依奈特制药公司 用于调节nk细胞活性的组合物和方法
CN104645327A (zh) 2003-07-24 2015-05-27 依奈特制药公司 使用nk细胞增效化合物提高治疗性抗体功效的方法和组合物
CA2551084C (en) 2003-12-02 2014-07-15 Alfred Knox Harpole Rackable collapsible stackable unit

Also Published As

Publication number Publication date
KR20060038461A (ko) 2006-05-03
KR101299599B1 (ko) 2013-08-23
AU2004258747B2 (en) 2009-11-19
US20110008335A1 (en) 2011-01-13
DK1648507T3 (en) 2017-05-01
CN102772798B (zh) 2016-01-13
NO337619B1 (no) 2016-05-09
BRPI0412890A (pt) 2006-10-03
US9090876B2 (en) 2015-07-28
NO341586B1 (no) 2017-12-11
AU2004258747A1 (en) 2005-02-03
EP2292264A3 (en) 2012-12-19
CN104645327A (zh) 2015-05-27
IL172679A (en) 2011-04-28
EP2292264A2 (en) 2011-03-09
CN1829530A (zh) 2006-09-06
PL1648507T3 (pl) 2017-07-31
HRP20170342T1 (hr) 2017-05-19
HUE033129T2 (en) 2017-11-28
JP6290751B2 (ja) 2018-03-07
RU2396981C2 (ru) 2010-08-20
PT1648507T (pt) 2017-03-20
CA2532547A1 (en) 2005-02-03
IL172679A0 (en) 2006-04-10
BRPI0412890B8 (pt) 2021-05-25
ES2619171T3 (es) 2017-06-23
NO20150493L (no) 2006-01-24
SI1648507T1 (sl) 2017-07-31
CA2532547C (en) 2020-02-25
EP1648507B1 (en) 2017-01-25
US20150299319A1 (en) 2015-10-22
CN102772798A (zh) 2012-11-14
BRPI0412890B1 (pt) 2019-05-14
JP2014240426A (ja) 2014-12-25
ZA200601584B (en) 2007-05-30
RU2006105642A (ru) 2006-06-27
NO20056049L (no) 2006-04-24
JP2006528626A (ja) 2006-12-21
US7803376B2 (en) 2010-09-28
JP5665702B2 (ja) 2015-02-04
US10059765B2 (en) 2018-08-28
JP5642328B2 (ja) 2014-12-17
EP1648507A1 (en) 2006-04-26
KR20120063562A (ko) 2012-06-15
LT1648507T (lt) 2017-04-25
US20050037002A1 (en) 2005-02-17
WO2005009465A1 (en) 2005-02-03
JP2012051889A (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
CY1118978T1 (el) Μεθοδοι και συνθεσεις για την αυξηση της αποτελεσματικοτητας των θεραπευτικων αντισωματων με τη χρηση ενωσεων που διεγειρουν τα κυτταρα νκ
CY1107682T1 (el) Παραγωγα 4-τετραζολυλ-4 φαινυλπιπεριδινης για θεραπεια πονου
CY1113190T1 (el) Μεθοδος αγωγης της αιμολυτικης νοσου
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
DK1408984T3 (da) Organofosforforbindelser til aktivering af gamma/delta T celler
CY1118349T1 (el) Παραγοντες συνδεσης me cd19 και χρησεις αυτων
EA201100128A1 (ru) АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
CY1117617T1 (el) Αντισωματα ige εναντι ανθρωπου υψηλης συναφειας
CY1118096T1 (el) Ρυθμιστες υποδοχεα οπιοειδους
PA8556201A1 (es) Alquinos como inhibidores de metaloproteinasa de matriz
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
CR9819A (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
CY1112516T1 (el) Ενωσεις 2,4-πυριμιδινοδιαμινης και οι χρησεις τους
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
EA200301215A1 (ru) Лиганды рецепторов 5-ht и их применение
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
CY1115012T1 (el) Μεθοδος συστηματικης εξετασης παρασκευασματων παρασιτου για αποτελεσματικοτητα στην αποτροπη και ελεγχο ασθενειων
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
EA200970251A1 (ru) Антитела к миостатину
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения